What is Regulatory Medical Writing and Where is it Used?

Regulatory medical writing plays a crucial role in the pharmaceutical and biotechnology industries. It ensures that critical clinical and non-clinical data are appropriately documented and communicated to regulatory authorities, supporting the regulatory review and ongoing monitoring of medicinal products. This blog provides a comprehensive overview of regulatory medical writing, its importance, key documents, and industry best practices.

In Brief

• Regulatory medical writing presents clinical and non-clinical evidence in a form suited to a specific document, audience, and regulatory jurisdiction.
• It supports clinical development by helping health authorities and other stakeholders assess evidence clearly and consistently.
• Regulatory medical writers contribute to protocols, Investigator's Brochures (IBs), Clinical Study Reports (CSRs), submission content, and post-authorisation documents.
• Clear writing cannot determine a regulatory outcome, and incomplete data, conflicting reviews, and compressed timelines can still affect document quality.
  
  

What is regulatory medical writing?

Regulatory medical writing involves the preparation of scientific documents required by regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global health authorities. These documents must adhere to applicable guidelines and accurately present clinical trial results, drug safety data, and other critical information.

The purpose of regulatory medical writing is to present scientific evidence in a form that meets the requirements of the document, its intended audience, and the relevant regulatory jurisdiction. This involves interpreting and explaining the underlying evidence.

Regulatory medical writers must understand the purpose and structure of each document, identify relevant information from approved sources and present it clearly and consistently. The content, terminology and level of detail will vary according to the development stage and intended audience.

The importance of regulatory writing

Regulatory writing supports drug development, ensuring that relevant data are communicated accurately, consistently, and in line with applicable requirements. This includes the following:

1. Compliance with Regulatory Guidelines
   
   Ensures that documents meet regulatory expectations, which can reduce avoidable questions, rework, and document-related delays.
   
   
2. Supports Regulatory Review
   
   Clear, complete, and internally consistent documents help reviewers assess the evidence efficiently. Document quality alone, however, cannot determine the outcome or timing of a regulatory application.
   
   
3. Enhances Patient Safety
   
   Clearly documented safety and efficacy data support informed decision-making.
   
   
4. Interpretation and Summarisation of Complex Data
   
   Regulatory writers understand, interpret, and summarise complex scientific and statistical data while providing effective guidance to clinical study teams, which typically include experts from clinical/medical, statistics, regulatory affairs, pharmacovigilance, and pharmacology.
   
   

How does regulatory writing differ from scientific writing?

Regulatory writing and scientific writing both communicate medical and scientific information, but they serve different purposes. Regulatory writing supports clinical development, regulatory review and the maintenance of product approvals. Its principal audiences can include health authorities, ethics committees, investigators and other clinical development stakeholders.

Scientific or publication writing usually communicates research findings through journal manuscripts, abstracts, posters and related materials. These outputs follow applicable journal and publication standards, while regulatory documents are more closely governed by document-specific guidance, templates and submission requirements.

Regulatory documents also need to remain consistent with the approved source data and related documents within a study or submission. This need for consistency and traceability affects how information is selected, interpreted and presented.

What are regulatory documents in clinical trials?

Regulatory writers produce a wide variety of clinical documents throughout the life cycle of a (potential) treatment, starting with describing and reporting data from clinical trials, through to preparing regulatory submission documents. If the treatment is approved by a regulatory authority, regulatory writers also produce post approval reports on the use of the treatment in patients.

The documents required will depend on the product, study, development stage, and regulatory strategy. They can be grouped broadly according to when and how they are used.

Study planning and conduct

During study planning and conduct, regulatory writers may support Clinical Study Protocols, Investigator’s Brochures (IBs) and informed consent documents. These documents explain why and how a study will be conducted and provide investigators, ethics committees and study participants with information relevant to their involvement.

Study reporting and regulatory submission

Once a study has been completed, regulatory writers may prepare Clinical Study Reports (CSR), study synopses and subject narratives. Submission-related work can include regulatory briefing documents, responses to health authority questions, and the clinical summaries and overviews included in the Common Technical Document.

Post-authorisation activities

After approval, regulatory writers may support aggregate safety reports, updates to product information, and other documents used to communicate safety information and assess a product’s benefit-risk profile.

Examples of clinical documents produced by regulatory writers most commonly include IBs, Clinical Study Protocols, CSRs, Informed consent documents, subject narratives, aggregate safety reports, regulatory briefing documents, and clinical summaries and overviews prepared for the CTD.

The intended audience depends on the document and may include regulatory authorities, ethics committees, investigators, study teams, or trial participants.

The CTD is a five-module structure used to organise administrative, quality, non-clinical and clinical information within a regulatory application. Regulatory medical writers commonly contribute to the clinical overviews and summaries in Module 2 and the clinical study documentation included in Module 5.

The electronic Common Technical Document, or eCTD, is the technical format used to submit and manage CTD-based applications electronically. The CTD determines how dossier content is organised, while the eCTD supports its electronic submission and lifecycle management. Accepted versions and implementation requirements can vary by regulatory authority.

The key national regulatory authorities are:

• United States - Food and Drug Administration (FDA)
• European Union - European Medicines Agency (EMA)
• Japan - Ministry of Health, Labour and Welfare Japan and the Pharmaceuticals and Medical Devices Agency (PMDA)
• United Kingdom - Medicines & Healthcare Products Regulatory Agency (MHRA)
• Canada - Health Canada
• Australia - Therapeutic Goods Administration (TGA)

Although these authorities work towards similar objectives, their administrative processes, submission terminology and regional documentation requirements can differ. Regulatory writers therefore need to consider both internationally recognised guidance and jurisdiction-specific requirements.

How are regulatory documents developed and reviewed?

The precise process varies by organisation and document type, but regulatory document development usually involves four connected stages.

1. Planning and source review
   
   The writer confirms the document’s purpose, audience, applicable guidance, approved source material, contributors, review process and timeline.
   
   
2. Drafting
   
   The document is developed using the relevant template and source information. Claims and interpretations should be traceable to the underlying evidence, with uncertainties referred to the appropriate specialist.
   
   The writer also checks that the narrative is consistent with tables, figures, listings and related documents. If the source information is incomplete or inconsistent, the writer raises the issue with the relevant specialist rather than resolving it through an unsupported assumption.
   
   
3. Cross-functional and scientific review
   
   Clinical, medical, statistical, safety, regulatory and other relevant specialists review the document according to their responsibilities. Clear reviewer roles can help limit conflicting comments and unnecessary review cycles.
   
   
4. Quality control and finalisation
   
   Quality control checks verifiable information against approved sources and reviews consistency, completeness, terminology, references and formatting. Once comments have been resolved, the document proceeds through approval, publishing and finalisation.
   
   Version control should be maintained throughout the process so that contributors can identify the current draft, its review status and the changes made between versions.
   
   

What does a regulatory medical writer do?

A regulatory medical writer works with clinical, medical, statistical, regulatory, safety and operational specialists to develop documents for a defined purpose and audience. Their involvement can begin with document planning and continue through drafting, review, quality control and finalisation.

What skills does a regulatory medical writer need?

Regulatory medical writing requires scientific understanding, analytical ability, clear writing and project organisation. Writers need to understand clinical research methods, drug development and the terminology used in the relevant therapeutic area.

Statistical literacy is also important. Regulatory writers regularly work with study endpoints, analysis populations, confidence intervals and other statistical outputs. They need enough understanding to present the approved analyses accurately and recognise when an interpretation requires input from a statistician.

Depending on the assigned documents, writers may also need an understanding of pharmacokinetics, which describes how the body affects a medicine, and pharmacodynamics, which describes the effects of the medicine on the body.

Because documents are developed collaboratively, regulatory medical writers must also manage input from multiple contributors, communicate unresolved issues clearly and maintain consistency across related documents. Attention to detail is important, but it must be combined with an understanding of the document’s overall purpose.

What are the main challenges in regulatory medical writing?

Regulatory documents are often developed while data, analyses and strategic decisions are still being finalised. This can create dependencies and revisions that need to be managed without losing consistency across the document set.

Source information may also be incomplete or inconsistent. For example, descriptions of study populations, endpoints or safety findings may differ between the protocol, statistical outputs and earlier documents. These differences need to be identified and resolved with the relevant study team members.

Cross-functional review presents another challenge. Reviewers may approach the document from different scientific, operational or regulatory perspectives, leading to conflicting comments or changes to previously agreed interpretations. Defined reviewer responsibilities and comment-resolution processes can help manage this risk.

Compressed timelines can increase the risk of errors, repeated review cycles and inconsistent updates across related documents.

Best practices in regulatory medical writing

There are several key guidelines and strategies to keep in mind for producing accurate, concise, and inspection-ready regulatory documents. These include:

Follow Regulatory Guidelines
Identify the guidance relevant to the document and jurisdiction. For example, ICH E3 covers the structure and content of CSRs, while the ICH M4 series covers the organisation of the CTD.

Ensure Clarity and Conciseness
Use clear and precise language to avoid misinterpretation.

Collaborate with Cross-Functional Teams
Work with clinical teams, statisticians, PK, PD and regulatory affairs professionals to ensure accurate documentation.

Maintain Version Control
Keep track of document revisions to ensure consistency and make the current review status clear.

Use Standard Templates
Follow applicable regulatory and sponsor templates for uniformity across documents.

Conduct Peer Review and Scientific Review
Engage subject matter experts to validate the accuracy and scientific integrity of the content.

Perform Quality Checks (QC)
Ensure document accuracy, completeness, and compliance with applicable requirements before finalisation.

Adhere to Processes, Templates, and Data Sources
Ensure documentation is suitable for its intended regulatory use by following established processes, utilising templates, and verifying data sources for accuracy.

References to ICH E6 should identify the applicable revision rather than referring to ICH E6 generically. ICH E6(R3) introduced revised Good Clinical Practice principles and a more proportionate, risk-based approach to trial quality. As implementation can vary between jurisdictions, study teams should confirm which revision and regional requirements apply.

Conclusion

Regulatory medical writing is a specialised discipline that plays a pivotal role in drug development and regulatory submissions. It requires a combination of scientific expertise, writing proficiency, and adherence to regulatory requirements.

Quanticate offers a wide range of medical writing services including regulatory writing, publication writing, transparency writing and safety writing in support of any or all stages of the pharmaceutical development life cycle. Our medical writers deliver accurate, timely and cost-effective documents to high ethical and scientific standards. Our team is trusted by top pharma and flexible in our ability to adapt to client systems and standard operating procedures (SOPs). Please request a consultation below if you would like to speak to a member of our team who can support your trial.